Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083354 | 0.84 | LMNA (0.47) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL14430757 | 0.81 | LMNA (0.44) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL9331500 | 0.79 | HSD17B10 (0.47) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL8197650 | 0.77 | LMNA (0.48) | LMNAHTTKDM4EGAAALDH1A1 | |
| SCHEMBL10874720 | 0.77 | POLB (0.48) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL27865228 | 0.77 | LMNA (0.40) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL3672142 | 0.76 | KDM4E (0.44) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL11579831 | 0.76 | KDM4E (0.44) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL5598390 | 0.74 | LMNA (0.45) | LMNABACE1HTTKDM4EHSD17B10 | |
| SCHEMBL13140672 | 0.74 | KDM4E (0.43) | LMNABACE1HTTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6974876-B2 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-12-04 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6570027-B2 | Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2002-10-31 | — | — | US | disclosed |
| US-6388094-B1 | FORMING AN AMINOEPOXIDE | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| EP-0855388-B1 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | SEARLE & CO (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6127556-A | Epoxide formation by continuous in-situ synthesis process | G. D. SEARLE & CO. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0730570-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2000-04-19 | — | — | EP | disclosed |
| US-6022996-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5872298-A | Method of preparing intermediates for retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5872299-A | Method of preparing intermediates for retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0855388-A2 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5583238-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | LMNA 1483/4885BACE1 84/4885HTT 2793/4885 |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | LMNA 1522/4885BACE1 87/4885HTT 2865/4885 |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | LMNA 1483/4885BACE1 84/4885HTT 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.